AGM
MRKR icon

Alpine Global Management’s Marker Therapeutics MRKR Stock Holding History

Alpine Global Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,560
Closed -$103K – 91
2019
Q1 		$103K Sell
1,560
-424
-21% -$24.8K 0.03% 83
2018
Q4 		$110K Buy
+1,984
New +$145K 0.03% 208

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alpine Global Management's MRKR Position: Q2 2019 in Review

Alpine Global Management sold out of Marker Therapeutics (MRKR) in Q2 2019, closing a stake of 1,560 shares — an estimated $103K sold.

Alpine Global Management first reported a position in MRKR in Q4 2018 and held it in 2 quarters. The position peaked at $110K in Q4 2018. 70 funds tracked by Wall St. Rank hold MRKR as of Q2 2019.

  • Alpine Global Management reported no remaining Marker Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Alpine Global Management sold 1,560 Marker Therapeutics shares in Q2 2019, an estimated $103K.
  • Alpine Global Management first reported a position in Marker Therapeutics in Q4 2018 and held it in 2 quarters.
  • Alpine Global Management's Marker Therapeutics position peaked at $110K in Q4 2018.
  • 70 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2019.

Based on Alpine Global Management's 13F filing for Q2 2019, filed 12 Jul 2019.